Skip to main content
SpringerLink
Log in

Hepatozelluläres Karzinom (HCC)

  • Chapter
Kompendium Internistische Onkologie

  • 107 Accesses

Zusammenfassung

Häufigkeit: Obwohl mit etwa 1–2% eine vergleichsweise seltene maligne Erkrankung in den USA, ist es mit 20–30% das häufigste Malignom in Teilen von Asien und Afrika.Weltweit ist das HCC die fünfthäufigste maligne Erkrankung und verursacht etwa 1 Mio. Todesfälle pro Jahr.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Barbare J, Milan C, Bouché O et al (2002) Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen: a phase III trial in 420 patients. Proc Am Soc Clin Oncol 21: abstr. 551

    Google Scholar 

  • Bismuth H, Majno PE, Adam R (1999) Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19:311–322

    Article  PubMed  CAS  Google Scholar 

  • Bobbio-Pallavicini E, Porta C, Moroni M et al (1997) Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33:1784–1788

    Article  PubMed  CAS  Google Scholar 

  • Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 88:912–920

    Article  PubMed  CAS  Google Scholar 

  • Chang CH, Chau GY, Lui WY et al (2004) Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 139:320–325; discussion 326

    Article  PubMed  Google Scholar 

  • Chow P, Kiat TC, Choo TB et al (1998) Tamoxifen in hepatocellular carcinoma. Lancet 352:819–820

    Article  PubMed  CAS  Google Scholar 

  • Chow PK, Tai BC, Tan CK et al (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 36:1221–1226

    Article  PubMed  CAS  Google Scholar 

  • Cillo U, Vitale A, Bassanello M et al (2004) Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239:150–159

    Article  PubMed  Google Scholar 

  • Cillo U, Bassanello M, Vitale A et al (2004) The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 40:124–131

    Article  PubMed  Google Scholar 

  • CLIP Group (Cancer of the Liver Italian Programme) (1998) Tamoxifen in treatmentof hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 352:17–20

    Article  Google Scholar 

  • De la Revilla NJ, Moreno JM, Rubio E et al (2003) Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. Transplant Proc 35:1830–1831

    Article  PubMed  CAS  Google Scholar 

  • Esnaola N, Vauthey JN, Lauwers G (2002) Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma (Br J Surg 2002; 89:57–62). Br J Surg 89:939–940; author reply 940

    Article  PubMed  CAS  Google Scholar 

  • Falkson G, MacIntyre JM, Schutt AJ et al (1984) Neocarcinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 2:581–584

    PubMed  CAS  Google Scholar 

  • Hemming AW, Reed AI, Langham MR Jr et al (2004) Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann Surg 239:712–721

    Article  PubMed  Google Scholar 

  • Ishikawa T, Ichida T, Sugitani S et al (2001) Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 16:452–459

    Article  PubMed  CAS  Google Scholar 

  • Iwatsuki S, Starzl TE, Sheahan DG et al (1991) Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214:221–228; discussion 228–229

    Article  CAS  Google Scholar 

  • Izzo F, Marra P, Beneduce G et al (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22:1815–1822

    Article  PubMed  CAS  Google Scholar 

  • Katzenstein HM, Krailo MD, Malogolowkin MH et al (2003) Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 97:2006–2012

    Article  PubMed  Google Scholar 

  • Knechtle SJ (2004) Challenging choices: liver transplantation for hepatocellular carcinoma. Ann Surg 239:160–161

    Article  PubMed  Google Scholar 

  • Kouroumalis E, Skordilis P, Thermos K et al (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447

    Article  PubMed  CAS  Google Scholar 

  • Lauwers GY, Terris B, Baus UJ et al (2002) Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 26:25–34

    Article  PubMed  Google Scholar 

  • Liu JH, Chen PW, Asch SM et al (2004) Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol 11:298–303

    Article  PubMed  Google Scholar 

  • Livraghi T, Giorgio A, Mann G et al (1995) Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197:101–108

    PubMed  CAS  Google Scholar 

  • Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429–442

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Bruix J, Fuster J et al (1998) Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 27:1572–1577

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917

    Article  PubMed  Google Scholar 

  • Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Sala M, Castells L et al (2000) Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31:54–58

    Article  PubMed  CAS  Google Scholar 

  • Mathurin P, Raynard B, Dharancy S et al (2003) Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 17:1247–1261

    Article  PubMed  CAS  Google Scholar 

  • Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas inãtients with cirrhosis. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  • Melia WM Johnson P, Williams R (1987) Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71:1213–1216

    PubMed  CAS  Google Scholar 

  • Nowak A, Chow PKH, Findlay M (2004) Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 40:1474–1484

    Article  PubMed  CAS  Google Scholar 

  • Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928

    Article  PubMed  CAS  Google Scholar 

  • Panis Y, Rad AR, Boyer O et al (1996) Gene therapy for liver tumors. Surg Oncol Clin N Am 5:461–473

    PubMed  CAS  Google Scholar 

  • Patt YZ, Hassan MM, Lozano RD et al (2003) Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21:421–427

    Article  PubMed  CAS  Google Scholar 

  • Patt YZ, Hassan MM, Aguayo A et al (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101:578–586

    Article  PubMed  CAS  Google Scholar 

  • Philip P, Mahoney M, Thomas J et al (2004) Phase II trial of OSI-774 in patients with hepatocellular and biliary cancer. Proc GI ASCO Symp 1:abstr. 174

    Google Scholar 

  • Pons-Renedo F, Llovet JM (2003) Hepatocellular carcinoma: a clinical update. Med-GenMed 5:11

    Google Scholar 

  • Poon RT, Fan ST, Tsang FH et al (2002) Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 235:466–486

    Article  PubMed  Google Scholar 

  • Riestra S, Rodriguez M, Delgado M et al (1998) Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 26:200–203

    Article  PubMed  CAS  Google Scholar 

  • Ringe B, Pichlmayr R, Wittekind C et al (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15:270–285

    Article  PubMed  CAS  Google Scholar 

  • Roayaie S, Schwartz JD, Sung MW et al (2004) Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 10:534–540

    Article  PubMed  Google Scholar 

  • Schwartz JD, Schwartz M, Mandeli J et al (2002) Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3:593–603

    Article  PubMed  Google Scholar 

  • Strumberg D, Erhard J, Harstrick A et al (1998) Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer 34:1290–1292

    Article  PubMed  CAS  Google Scholar 

  • Taleb J, Bonyhay L, Golli L et al (2003) Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98:2664–2670

    Article  CAS  Google Scholar 

  • Uto H, Ido A, Hon T et al (1999) Hepatoma-specific gene therapy through retrovirusmediated and targeted gene transfer using an adenovirus carrying the ecotropic receptor gene. Biochem Biophys Res Commun 265:550–555

    Article  PubMed  CAS  Google Scholar 

  • Varela M, Sala M, Llovet J et al (2003) Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev 29:99–104

    Article  PubMed  Google Scholar 

  • Vauthey JN, Lauwers GY, Esnaola NF et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536

    Article  PubMed  Google Scholar 

  • Wayne JD, Lauwers GY, Ikai I et al (2002) Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 235:722–730; discussion 730–721

    Article  PubMed  Google Scholar 

  • Yang T, Chang W, Lin Z et al (2003) A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 22:336, abstr. 1351

    Google Scholar 

  • Yao FY, Ferrell L, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403

    Article  PubMed  CAS  Google Scholar 

  • Yoo HY, Patt CH, Geschwind JF et al (2003) The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21:4329–4335

    Article  PubMed  Google Scholar 

  • Yuen MF, Poon RT, Lai CL et al (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36:687–691

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Grothey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Strumberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Grothey, A., Strumberg, D., Gebel, M. (2006). Hepatozelluläres Karzinom (HCC). In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_218

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_218

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation